OKYO Pharma's Urcosimod Phase 2 Data Accepted for Presentation at Prestigious ASCRS Meeting
OKYO has more than doubled off its 52-week low of $0.902.
Summary
OKYO Pharma announced that efficacy and safety data from its Phase 2 study of urcosimod for neuropathic corneal pain has been accepted for presentation at the 2026 ASCRS Annual Meeting, providing external validation for its lead candidate.
Key Events · Product Development and Regulatory · OKYO
-
Phase 2 Data Accepted for ASCRS Presentation
An abstract detailing efficacy and safety results from the proof-of-concept Phase 2 study of urcosimod for neuropathic corneal pain (NCP) has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
-
Validation of Lead Candidate
This acceptance, following a competitive review process, provides external validation for urcosimod's potential as a novel therapeutic for NCP, building on previously announced positive efficacy signals.
-
Supports Upcoming Phase 2b/3 Trial
The presentation will share these results with leading ophthalmologists, advancing development efforts towards a planned 150-patient Phase 2b/3 multiple-dose study of urcosimod for NCP, expected to initiate in the first half of 2026, following recent FDA alignment on trial design on January 28, 2026.
Analysis · OKYO · Life Sciences
OKYO Pharma's announcement of its urcosimod Phase 2 data acceptance for presentation at the ASCRS Annual Meeting provides significant external validation for its lead candidate. This recognition from a prestigious scientific body reinforces the positive efficacy and safety signals previously observed in the proof-of-concept study for neuropathic corneal pain. The presentation will increase visibility among key ophthalmologists and supports the company's strategic path towards initiating a larger Phase 2b/3 trial in the first half of 2026, a plan recently aligned with the FDA. This event builds positive momentum for the company's clinical development efforts.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1944 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OKYO was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.7M. The 52-week trading range was $0.90 to $3.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.